@TumorBoardTues #TumorBoardTuesday 1/9📣
68 year old man p/w lower GI bleed requiring 7 units pRBCs, found to have cecal adenoca + 2 liver metastases (1.6 cm and 0.7 cm), subcm lung nodules
➡️right hemicolectomy and liver biopsy: pT3pN1b(3/27)pM1b, stage IVB disease, MSS, KRAS MT, what next?
@TumorBoardTues #TumorBoardTuesday 2/9
Patient recovers ➡️ FOLFOX c/b esophageal spasm vs. coronary vasospasm (no EKG changes but RBBB at baseline), occurs despite omitting oxaliplatin (unable to tolerate infusional 5-FU), stopped after 4 cycles
Given 1 dose of iri c/b C diff colitis, CT: SD
@TumorBoardTues Complete disclosure: this CT was stable, but some of the lung nodules were slightly smaller, indicating
they could be real
@TumorBoardTues #TumorBoardTuesday 3/9
➡️left liver lobectomy and wedge seg 8, 4 foci of metastatic disease removed ➖margins, CT now with slight growth of lung nodules.
➡️ very low dose capecitabine (500 mg daily) and titrated up, lung lesions grow
➡️ RLLobectomy: ➕metastatic disease
@TumorBoardTues #TumorBoardTuesday 4/9
NGS on the lung resection path reveals KRAS G12D, MSS, low TMB (6), PD-L1 negative, 2 mutations in APC, a TP53 mutation, ERBB2 non-amplified, and a POMK-NRG1 fusion…

What’s an NRG1 fusion???
@TumorBoardTues #TumorBoardTuesday 5/9
NRG1 fusions create a ligand for the ERBB3 receptor, inducing heterodimerization with ERBB2 and downstream activation of PI3K-AKT and MAPK pathways

Fernandez-Cuesta and Thomas. Clinical Cancer Research 2015. @CCR_AACR
@TumorBoardTues @CCR_AACR #TumorBoardTuesday 6/9
NRG1 fusions are seen at low frequency across malignancies:

Jonna et al. Clinical Cancer Research 2019. @SushmaJonna @StephenVLiu @CCR_AACR clincancerres.aacrjournals.org/content/25/16/…
@TumorBoardTues @CCR_AACR @SushmaJonna @StephenVLiu #TumorBoardTuesday 7/9
NRG1 fusions are potentially targetable by drugs blocking HER:
➡️ Afatinib (pan-HER TKI)
➡️ Tarloxitinib (hypoxia-released prodrug, pan-HER inhibitor)
➡️ Zenocutuzumab (docks on HER2 and blocks NRG1-fusion binding with HER3)
➡️ Seribantumab (anti-HER3 mAb)
@TumorBoardTues POMK was a novel fusion partner and this is the only known CRC patient with an NRG1 fusion - novel fusion partners would be missed without broad tissue-based NGS/WES
@TumorBoardTues @CCR_AACR @SushmaJonna @StephenVLiu #TumorBoardTuesday 8/9
Back to our case➡️ afatinib 30 mg daily
had stable disease for 4 months with initial decline in CEA, stayed on drug for 16 months and received multiple local therapies to liver, chest wall, and duodenal lymph node

theoncologist.onlinelibrary.wiley.com/doi/10.1634/th… @OncJournal
@TumorBoardTues @CCR_AACR @SushmaJonna @StephenVLiu So sorry, I misspelled tarloxotinib!!
@TumorBoardTues @CCR_AACR @SushmaJonna @StephenVLiu @OncJournal #TumorBoardTuesday 9/9
➡️ Profiling can reveal rare targetable genetic alterations even in patients with known driver mutations
➡️ NRG1 fusions are seen at low frequencies across tumor types, enriched in RAS-WT panc ca
➡️ Drugs 🏹HER may have act against NRG1+ tumors

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Benjamin Weinberg, MD, FACP

Benjamin Weinberg, MD, FACP Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!